- Home
- NITO vs LIXT Comparison
NITO vs LIXT Comparison
Compare NITO & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NITO
- LIXT
- Stock Information
- Founded
- NITO 2009
- LIXT 2005
- Country
- NITO Israel
- LIXT United States
- Employees
- NITO N/A
- LIXT N/A
- Industry
- NITO
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- NITO
- LIXT Health Care
- Exchange
- NITO NYSE
- LIXT Nasdaq
- Market Cap
- NITO 4.2M
- LIXT 4.1M
- IPO Year
- NITO N/A
- LIXT N/A
- Fundamental
- Price
- NITO $0.30
- LIXT $1.33
- Analyst Decision
- NITO
- LIXT
- Analyst Count
- NITO 0
- LIXT 0
- Target Price
- NITO N/A
- LIXT N/A
- AVG Volume (30 Days)
- NITO 5.5M
- LIXT 22.1K
- Earning Date
- NITO 05-15-2025
- LIXT 05-12-2025
- Dividend Yield
- NITO N/A
- LIXT N/A
- EPS Growth
- NITO N/A
- LIXT N/A
- EPS
- NITO N/A
- LIXT N/A
- Revenue
- NITO $232,000.00
- LIXT N/A
- Revenue This Year
- NITO N/A
- LIXT N/A
- Revenue Next Year
- NITO N/A
- LIXT N/A
- P/E Ratio
- NITO N/A
- LIXT N/A
- Revenue Growth
- NITO 24.74
- LIXT N/A
- 52 Week Low
- NITO $0.16
- LIXT $1.02
- 52 Week High
- NITO $3.49
- LIXT $3.50
- Technical
- Relative Strength Index (RSI)
- NITO 49.96
- LIXT 50.90
- Support Level
- NITO $0.25
- LIXT $1.16
- Resistance Level
- NITO $0.30
- LIXT $1.49
- Average True Range (ATR)
- NITO 0.03
- LIXT 0.11
- MACD
- NITO -0.00
- LIXT 0.00
- Stochastic Oscillator
- NITO 67.66
- LIXT 51.45
About NITO N2OFF INC
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork. The Company has two reportable segments: Pathogen prevention and prolong shelf life, and the N2O emissions Global warming solutions.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.